Followed by Keytruda, Opdivo completed in landing into ‘Big 5’ hospitals

‘Opdivo,’ an immunotherapy cooperated by BMS and Ono Pharmaceutical, entered Seoul National University Hospital, completing the landing process into the ‘Big 5’ hospitals.

According to the industry concerned on the 26^th, Seoul National University Hospital pushed through 9 drugs including Opdivo(nivolumab), the PD-1 inhibitor, at its recent drug committee(DC).

Thus, both of the two PD-1 inhi...